ACA
CYTK icon

Avoro Capital Advisors’s Cytokinetics CYTK Stock Holding History

Avoro Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426M Buy
4,999,999
+1,666,666
+50% +$120M 3.82% 9
2026
Q1 		$220M Buy
+3,333,333
New +$212M 2.16% 16
2016
Q3 		– Sell
-503,900
Closed -$4.78M – 49
2016
Q2 		$4.78M Buy
+503,900
New +$4.13M 1.06% 23

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Avoro Capital Advisors's CYTK Position: Q2 2026 in Review

Avoro Capital Advisors increased its Cytokinetics (CYTK) stake by 50% in Q2 2026, buying an estimated $120M and bringing the position to 4,999,999 shares worth $426M. The position accounts for 3.82% of the portfolio, ranked #9.

Avoro Capital Advisors first reported a position in CYTK in Q2 2016 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Avoro Capital Advisors held 4,999,999 shares of Cytokinetics worth $426M as of Q2 2026.
  • Avoro Capital Advisors bought 1,666,666 Cytokinetics shares in Q2 2026, an estimated $120M.
  • Cytokinetics made up 3.82% of Avoro Capital Advisors's portfolio in Q2 2026, its #9 holding.
  • Avoro Capital Advisors first reported a position in Cytokinetics in Q2 2016 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.